1.Alberti, K. G. M. M., P. Zimmet, and J. Shaw, Metabolic syndrome—a new world‐wide definition. A consensus statement from the international diabetes federation. Diabetic medicine, 2006. 23(5): p. 469–480.
2.Viana Abranches, M., et al., Obesity and diabetes: The link between adipose tissue dysfunction and glucose homeostasis. Nutrition research reviews, 2015. 28: p. 121–132.
3.Lovren, F., H. Teoh, and S. Verma, Obesity and Atherosclerosis: Mechanistic Insights. The Canadian journal of cardiology, 2015. 31: p. 177–183.
4.Barroso, T. A., et al., Association of central obesity with the incidence of cardiovascular diseases and risk factors. International Journal of Cardiovascular Sciences, 2017. 30(5): p. 416–424.
5.Okafor, C. I., The metabolic syndrome in Africa: Current trends. Indian journal of endocrinology and metabolism, 2012. 16(1): p. 56.
6.Young, F., et al., A review of co-morbidity between infectious and chronic disease in Sub Saharan Africa: TB and diabetes mellitus, HIV and metabolic syndrome, and the impact of globalization. Globalization and health, 2009. 5(1): p. 9.
7.Romieu, I., et al., Energy balance and obesity: what are the main drivers? Cancer Causes & Control, 2017. 28(3): p. 247–258.
8.Peer, N., et al., High prevalence of metabolic syndrome in the Black population of Cape Town: the Cardiovascular Risk in Black South Africans (CRIBSA) study. European journal of preventive cardiology, 2015. 22(8): p. 1036–1042.
9.Oggioni, C., et al., Shifts in population dietary patterns and physical inactivity as determinants of global trends in the prevalence of diabetes: an ecological analysis. Nutrition, Metabolism and Cardiovascular Diseases, 2014. 24(10): p. 1105–1111.
10.Pradeilles, R., et al., Socio-economic influences on anthropometric status in urban South African adolescents: sex differences in the Birth to Twenty Plus cohort. Public health nutrition, 2015. 18(16): p. 2998–3012.
11.Rodríguez-Hernández, H., et al., Obesity and inflammation: epidemiology, risk factors, and markers of inflammation. International journal of endocrinology, 2013. 2013.
12.Mingrone, G. and M. Castagneto, The Pathophysiology of Obesity, in Minimally Invasive Bariatric and Metabolic Surgery. 2015, Springer. p. 17–23.
13.Twig, G., et al., Severe obesity and cardio-metabolic comorbidities: a nationwide study of 2.8 million adolescents. International Journal of Obesity, 2019. 43(7): p. 1391.
14.Zhou, J. and G. Qin, Adipocyte dysfunction and hypertension. American journal of cardiovascular disease, 2012. 2(2): p. 143.
15.Castro, A., L. Macedo-de la Concha, and C. Pantoja-Meléndez, Low-grade inflammation and its relation to obesity and chronic degenerative diseases. Revista Médica del Hospital General de México, 2017. 80(2): p. 101–105.
16.Kotsis, V., et al., Obesity, Hypertension, and Dyslipidemia. Obesity: Pathogenesis, Diagnosis, and Treatment, 2019: p. 227–241.
17.Mechanick, J. I., S. Zhao, and W. T. Garvey, The adipokine-cardiovascular-lifestyle network: Translation to clinical practice. Journal of the American College of Cardiology, 2016. 68(16): p. 1785–1803.
18.Heilbronn, L., S. Smith, and E. Ravussin, Failure of fat cell proliferation, mitochondrial function and fat oxidation results in ectopic fat storage, insulin resistance and type II diabetes mellitus. International journal of obesity, 2004. 28(S4): p. S12.
19.Heinonen, S., et al., Adipocyte morphology and implications for metabolic derangements in acquired obesity. International journal of obesity, 2014. 38(11): p. 1423.
20.Skurk, T., et al., Relationship between adipocyte size and adipokine expression and secretion. The Journal of Clinical Endocrinology & Metabolism, 2007. 92(3): p. 1023–1033.
21.Klöting, N. and M. Blüher, Adipocyte dysfunction, inflammation and metabolic syndrome. Reviews in Endocrine and Metabolic Disorders, 2014. 15(4): p. 277–287.
22.Blüher, M., Adipose tissue dysfunction contributes to obesity related metabolic diseases. Best practice & research Clinical endocrinology & metabolism, 2013. 27(2): p. 163–177.
23.Balistreri, C. R., C. Caruso, and G. Candore, The role of adipose tissue and adipokines in obesity-related inflammatory diseases. Mediators of inflammation, 2010. 2010.
24.Kissebah, A. H., et al., Relation of body fat distribution to metabolic complications of obesity. The Journal of Clinical Endocrinology & Metabolism, 1982. 54(2): p. 254–260.
25.Krotkiewski, M., et al., Impact of obesity on metabolism in men and women. Importance of regional adipose tissue distribution. The Journal of clinical investigation, 1983. 72(3): p. 1150–1162.
26.Amato, M. C., et al., Visceral Adiposity Index: a reliable indicator of visceral fat function associated with cardiometabolic risk. Diabetes Care, 2010. 33(4): p. 920–2.
27.Misra, A. and L. Khurana, Obesity-related non-communicable diseases: South Asians vs White Caucasians. International journal of obesity, 2011. 35(2): p. 167.
28.Snijder, M. B., et al., Associations of hip and thigh circumferences independent of waist circumference with the incidence of type 2 diabetes: the Hoorn Study. The American journal of clinical nutrition, 2003. 77(5): p. 1192–1197.
29.Tanko, L. B., et al., Peripheral adiposity exhibits an independent dominant antiatherogenic effect in elderly women. Circulation, 2003. 107(12): p. 1626–1631.
30.Czernichow, S., et al., Comparison of waist-to-hip ratio and other obesity indices as predictors of cardiovascular disease risk in people with type–2 diabetes: a prospective cohort study from ADVANCE. European Journal of Cardiovascular Prevention & Rehabilitation, 2011. 18(2): p. 312–319.
31.Pagano, E. S., E. Spinedi, and J. J. Gagliardino, White adipose tissue and circadian rhythm dysfunctions in obesity: pathogenesis and available therapies. Neuroendocrinology, 2017. 104(4): p. 347–363.
32.Flegal, K. M., et al., Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. Jama, 2013. 309(1): p. 71–82.
33.Manu, P., et al., Dysmetabolic signals in “metabolically healthy” obesity. Obesity research & clinical practice, 2012. 6(1): p. e9-e20.
34.Samocha-Bonet, D., et al., Insulin-sensitive obesity in humans–a ‘favorable fat’phenotype? Trends in Endocrinology & Metabolism, 2012. 23(3): p. 116–124.
35.Denis, G. V. and M. S. Obin, ‘Metabolically healthy obesity’: origins and implications. Molecular aspects of medicine, 2013. 34(1): p. 59–70.
36.Fan, H., et al., Abdominal obesity is strongly associated with cardiovascular disease and its risk factors in elderly and very elderly community-dwelling Chinese. Scientific reports, 2016. 6: p. 21521.
37.Després, J.-P., Abdominal obesity and cardiovascular disease: is inflammation the missing link? Canadian Journal of Cardiology, 2012. 28(6): p. 642–652.
38.Peer, N., K. Steyn, and N. Levitt, Differential obesity indices identify the metabolic syndrome in Black men and women in Cape Town: the CRIBSA study. Journal of Public Health, 2015. 38(1): p. 175–182.
39.Schmidt, F. M., et al., Inflammatory cytokines in general and central obesity and modulating effects of physical activity. PloS one, 2015. 10(3): p. e0121971.
40.Després, J. P., Is visceral obesity the cause of the metabolic syndrome? Annals of medicine, 2006. 38(1): p. 52–63.
41.Despres, J.-P., et al., Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk. Arteriosclerosis, thrombosis, and vascular biology, 2008. 28(6): p. 1039–1049.
42.Bakir, M. A., K. Hammad, and L. Mohammad, Prevalence of obesity, central obesity, and associated socio-demographic variables in Syrian women using different anthropometric indicators. AnthropologicAl review, 2017. 80(2): p. 191–205.
43.Kruger, M. J. and T. A. Nell, The prevalence of the metabolic syndrome in a farm worker community in the Boland district, South Africa. BMC public health, 2017. 17(1): p. 61–61.
44.Stewart, A., et al., International Standards for Anthropometric Assessment. Vol. 137. 2011.
45.De Onis, M. and J.-P. Habicht, Anthropometric reference data for international use: recommendations from a World Health Organization Expert Committee. The American journal of clinical nutrition, 1996. 64(4): p. 650–658.
46.Freedman, D. S. and A. A. Rimm, The relation of body fat distribution, as assessed by six girth measurements, to diabetes mellitus in women. American journal of public health, 1989. 79(6): p. 715–720.
47.Force, I. A. R. T., Type 2 diabetes clinical practice guidelines for Sub-Saharan Africa. Dar es Salaam: International Diabetes Federation Africa Region, 2006.
48.Amato, M. C., et al., Cut-off points of the visceral adiposity index (VAI) identifying a visceral adipose dysfunction associated with cardiometabolic risk in a Caucasian Sicilian population. Lipids in health and disease, 2011. 10(1): p. 183.
49.Organization, W. H., Waist circumference and waist-hip ratio: report of a WHO expert consultation, Geneva, 8–11 December 2008. 2011.
50.Finucane, M. M., et al., National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9· 1 million participants. The Lancet, 2011. 377(9765): p. 557–567.
51.Cois, A. and C. Day, Obesity trends and risk factors in the South African adult population. BMC obesity, 2015. 2(1): p. 42.
52.Nienaber-Rousseau, C., et al., Socio-demographic and lifestyle factors predict 5-year changes in adiposity among a group of black South African adults. International journal of environmental research and public health, 2017. 14(9): p. 1089.
53.Sartorius, B., et al., Rapidly increasing body mass index among children, adolescents and young adults in a transitioning population, South Africa, 2008–15. International journal of epidemiology, 2017.
54.Sahakyan, K. R., et al., Normal-weight central obesity: implications for total and cardiovascular mortality. Annals of internal medicine, 2015. 163(11): p. 827–835.
55.Owolabi, E. O., D. Ter Goon, and O. V. Adeniyi, Central obesity and normal-weight central obesity among adults attending healthcare facilities in Buffalo City Metropolitan Municipality, South Africa: a cross-sectional study. Journal of Health, Population and Nutrition, 2017. 36(1): p. 54.
56.Knowles, K., et al., Waist circumference, body mass index, and other measures of adiposity in predicting cardiovascular disease risk factors among Peruvian adults. International journal of hypertension, 2011. 2011.
57.Lam, B.C. C., et al., Comparison of body mass index (BMI), body adiposity index (BAI), waist circumference (WC), waist-to-hip ratio (WHR) and waist-to-height ratio (WHtR) as predictors of cardiovascular disease risk factors in an adult population in Singapore. PloS one, 2015. 10(4): p. e0122985.
58.Rodríguez, A., et al., Visceral and subcutaneous adiposity: are both potential therapeutic targets for tackling the metabolic syndrome? Current pharmaceutical design, 2007. 13(21): p. 2169–2175.
59.Fontana, L., et al., Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes, 2007. 56(4): p. 1010–1013.
60.Tchernof, A. and J.-P. Després, Pathophysiology of human visceral obesity: an update. Physiological reviews, 2013. 93(1): p. 359–404.
61.Schlecht, I., et al., Relations of visceral and abdominal subcutaneous adipose tissue, body mass index, and waist circumference to serum concentrations of parameters of chronic inflammation. Obesity facts, 2016. 9(3): p. 144–157.
62.Despres, J., Intra-abdominal obesity: an untreated risk factor for Type 2 diabetes and cardiovascular disease. Journal of endocrinological investigation, 2006. 29(3): p. 77.
63.Dyer, A. R. and P. Elliott, The INTERSALT study: relations of body mass index to blood pressure. INTERSALT Co-operative Research Group. Journal of human hypertension, 1989. 3(5): p. 299–308.
64.DYER, A. R., et al., Body Mass Index Versus Height And Weight In Relation To Blood Pressure Findings For The 10,079 Persons In Tee Intersalt Study. American journal of epidemiology, 1990. 131(4): p. 589–596.
65.Leggio, M., et al., The relationship between obesity and hypertension: an updated comprehensive overview on vicious twins. Hypertension Research, 2017. 40(12): p. 947.
66.Rosa, E. C., et al., Visceral obesity, hypertension and cardio-renal risk: a review. Arquivos Brasileiros de Endocrinologia & Metabologia, 2005. 49(2): p. 196–204.
67.Esser, N., et al., Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes research and clinical practice, 2014. 105(2): p. 141–150.
68.Stępień, M., et al., Obesity indices and inflammatory markers in obese non-diabetic normo-and hypertensive patients: a comparative pilot study. Lipids in health and disease, 2014. 13(1): p. 29.
69.Miller, M., Dyslipidemia and cardiovascular risk: the importance of early prevention. QJM: An International Journal of Medicine, 2009. 102(9): p. 657–667.
70.Wang, H. and D.-Q. Peng, New insights into the mechanism of low high-density lipoprotein cholesterol in obesity. Lipids in health and disease, 2011. 10(1): p. 176.
71.Klug, E., et al., South African Dyslipidaemia Guideline Consensus Statement: A joint statement from the South African Heart Association (SA Heart) and the Lipid and Atherosclerosis Society of Southern Africa (LASSA). Journal of Endocrinology, Metabolism and Diabetes of South Africa, 2012. 17(3): p. 155–165.
72.Klop, B., J. Elte, and M. Cabezas, Dyslipidemia in obesity: mechanisms and potential targets. Nutrients, 2013. 5(4): p. 1218–1240.
73.Tomkin, G. and D. Owens, Diabetes and dyslipidemia: characterizing lipoprotein metabolism. Diabetes, metabolic syndrome and obesity: targets and therapy, 2017. 10: p. 333.
74.Stone, N. J., et al., 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology, 2014. 63(25 Part B): p. 2889–2934.
75.Johnson, A.M. and J. M. Olefsky, The origins and drivers of insulin resistance. Cell, 2013. 152(4): p. 673–684.
76.Yusuf, S., et al., Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. The lancet, 2004. 364(9438): p. 937–952.
77.Williams, K. J. and I. Tabas, Lipoprotein retention—and clues for atheroma regression. 2005, Am Heart Assoc.
78.Sakakura, K., et al., Pathophysiology of atherosclerosis plaque progression. Heart, Lung and Circulation, 2013. 22(6): p. 399–411.
79.Reiger, S., et al., Awareness, treatment, and control of dyslipidemia in rural South Africa: The HAALSI (Health and Aging in Africa: A Longitudinal Study of an INDEPTH Community in South Africa) study. PloS one, 2017. 12(10): p. e0187347.
80.Aleksandrova, K., D. Mozaffarian, and T. Pischon, Addressing the perfect storm: biomarkers in obesity and pathophysiology of cardiometabolic risk. Clinical chemistry, 2018. 64(1): p. 142–153.
81.Park, H. S., J. Y. Park, and R. Yu, Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-α and IL–6. Diabetes research and clinical practice, 2005. 69(1): p. 29–35.
82.Monteiro, R. and I. Azevedo, Chronic inflammation in obesity and the metabolic syndrome. Mediators Inflamm, 2010. 2010.
83.Motala, A. A., et al., The prevalence of metabolic syndrome and determination of the optimal waist circumference cutoff points in a rural South African community. Diabetes care, 2011. 34(4): p. 1032–1037.
84.Zhao, D. and H. Liu, Adipose tissue dysfunction and the pathogenesis of metabolic syndrome. World Journal of Hypertension, 2013. 3(3): p. 18–26.
85.Weisberg, S. P., et al., Obesity is associated with macrophage accumulation in adipose tissue. The Journal of clinical investigation, 2003. 112(12): p. 1796–1808.
86.Bourlier, V., et al., Remodeling phenotype of human subcutaneous adipose tissue macrophages. Circulation, 2008. 117(6): p. 806.
87.Exley, M. A., et al., Interplay between the immune system and adipose tissue in obesity. Journal of Endocrinology, 2014. 223(2): p. R41-R48.
88.Lackey, D. E. and J. M. Olefsky, Regulation of metabolism by the innate immune system. Nature Reviews Endocrinology, 2016. 12(1): p. 15.
89.Cinti, S., et al., Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. Journal of lipid research, 2005. 46(11): p. 2347–2355.
90.Suganami, T., J. Nishida, and Y. Ogawa, A paracrine loop between adipocytes and macrophages aggravates inflammatory changes: role of free fatty acids and tumor necrosis factor α. Arteriosclerosis, thrombosis, and vascular biology, 2005. 25(10): p. 2062–2068.
91.Fuentes, E., et al., Mechanisms of chronic state of inflammation as mediators that link obese adipose tissue and metabolic syndrome. Mediators of inflammation, 2013. 2013.
92.Han, J. M. and M. K. Levings, Immune regulation in obesity-associated adipose inflammation. The Journal of Immunology, 2013. 191(2): p. 527–532.
93.Zheng, C., et al., Local proliferation initiates macrophage accumulation in adipose tissue during obesity. Cell death & disease, 2016. 7(3): p. e2167.
94.Engin, A. B., Adipocyte-macrophage cross-talk in obesity, in Obesity and Lipotoxicity. 2017, Springer. p. 327–343.
95.Lesna, I. K., et al., Human adipose tissue accumulation is associated with pro-inflammatory changes in subcutaneous rather than visceral adipose tissue. Nutrition & diabetes, 2017. 7(4): p. e264.
96.Lebovitz, H. E., Insulin resistance–a common link between type 2 diabetes and cardiovascular disease. Diabetes, Obesity and Metabolism, 2006. 8(3): p. 237–249.
97.Vella, C. A., et al., Associations of insulin resistance with cardiovascular risk factors and inflammatory cytokines in normal-weight Hispanic women. Diabetes Care, 2013. 36(5): p. 1377–1383.
98.Jaganathan, R., R. Ravindran, and S. Dhanasekaran, Emerging role of adipocytokines in type 2 diabetes as mediators of insulin resistance and cardiovascular disease. Canadian journal of diabetes, 2018. 42(4): p. 446–456. e1.
99.Kahn, S. E., R. L. Hull, and K. M. Utzschneider, Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature, 2006. 444(7121): p. 840.
100.Lukic, L., et al., Hypertension in obese type 2 diabetes patients is associated with increases in insulin resistance and IL–6 cytokine levels: potential targets for an efficient preventive intervention. International journal of environmental research and public health, 2014. 11(4): p. 3586–3598.
101.Lamarche, B., et al., Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease. Jama, 1998. 279(24): p. 1955–1961.